Homepage - Concussion Diagnosis

Reimagining Neuro Digital Assessment

Bringing Digital Devices to Life in a Neuro Platform

Parkinson's Disease

Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's.

Over 10 million people worldwide live with PD, with more than 1% of people over 70 affected.

Early stage Parkinson’s disease is difficult to diagnose with no specific objective test.

The number of people living with Parkinson's Disease in Europe today is expected to double to 2.4 million by 2030.

> 1 m

PEOPLE

worldwide are living with PD

0 k

pd cases

in Europe per year

1 k

pd cases

in the USA per year

Traumatic Brain Injury (Concussion)

Traumatic Brain Injury (TBI) or ‘concussion’ affects 69 million people globally per year.

Up to 50% of patients will not be fully recovered within six months and approximately 25% will not be able to resume work or study at the same level as before.

People carry on daily activities, risking their health often not knowing they have concussion.

In contact sports players are subject to experiencing a concussion with few objective solutions to support pitch-side assessment.

1 m

people

worldwide are estimated to sustain a mild Traumatic Brain Injury (mTBI) per year

1 m

cases

of Traumatic Brain Injury (TBI) occur in the USA per year

1 m

cases

of Traumatic Brain Injury (TBI) occur in Europe per year

Multiple Sclerosis

MS is the most common chronic inflammatory brain disease mediated by the immune system.

The number of people living with MS in Europe has increased more than 35% in the last 3 years, totalling >1m.

In some patients, diagnosing MS can be challenging due to the need to differentiate MS from other neuroinflammatory disorders, namely those of a demyelinating nature.

Most people are diagnosed between the ages of 20 and 50.

> 1 m

PEOPLE

worldwide are living with MS

new cases

are diagnosed each week in the USA

$ 1 b

annual cost

of MS to the USA economy

Stroke

Globally, there are >101 million people currently living who have experienced stroke.

One in four people >25 years will have a stroke in their lifetime.

6.5m people die from stroke annually.

Stroke is the leading cause of serious long-term disability in the US: two-thirds of US stroke survivors are currently disabled.

1 m

strokes

globally each year

1 k

strokes

in the US each year

1 m

strokes

in Europe each year

Parkinson's disease

Our mission and vision

We have developed, a handheld medical device for the rapid assessment and evaluation of brain impairment and brain disease. The device is unique in targeting a little-known physiological window into brain activity.

Our mission is to release the power of this biomarker into routine clinical use. Ultimately, we see the device being widely used in a range of conditions, including TBI, Parkinson’s Disease, stroke, and other degenerative brain diseases. In the short term, we will apply our technology to help radically improve the objectivity, accuracy and speed of diagnosis in mTBI and Parkinson’s Disease.

Our Objectives

Objective
Diagnosis

Fast and Accurate
Diagnosis

Reduce Cost of
Diagnosis

Better Patients
Outcomes

Our Solution

Platform
iTremor One

An Interoperable Neuro Platform with Connected Neuro Devices bringing real time neuro data to hospitals, neurologists, physicians and patients.

An intrinsic Neuro physiological biomarker and handheld medical device. (Note: The device is not CE marked or FDA approved yet and is currently for research purposes only.)